AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...

AstraZeneca has discontinued its CAPItello-280 phase three trial assessing Truqap, or capivasertib, in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic ...

The UK regulator has said eligible patients with prostate cancer will get early ... after three or more prior anti-androgen and chemotherapy regimens. "With over 11,500 prostate cancer deaths ...

HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic nucleotide analogue that kills nearby cancer cells. Together, this regimen is designed to induce an ...

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

in mCRPC patients previously treated with hormonal therapy and chemo. Merck’s run of bad results is unfortunately par for the course for checkpoint inhibitors in prostate cancer, with other ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

Chris Cotton tried cranberry juice to relieve the symptoms but a visit to the doctor eventually led to the devastating ...

Two weeks after taking an online "liver cancer cure," a 37-year-old man was brought back to hospital in a near-terminal state.

Hear the stories from the doctors, scientists and patients at the Arthur J.E. Child Comprehensive Cancer Centre ...